DB05108ExperimentalSmall molecule
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response...
- Mechanism
- Curator reviewed
Studies indicate that EHT899 may induce a secondary immune response against the virus, at the same time reducing the undesirable response associated with HBV infection. Oral intake of viral protein could, in some formulations, induce immunological suppression in chronic carriers.
- Primary indication
- Investigated for use/treatment in hepatitis (viral, B).Curator reviewed
- Code names
- EHT899
Which companies are running trials of EHT899, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account